SCHEMBL4059940

SCHEMBL4059940

COC(=O)CCc1ccnc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.50
▸ LOXL2 Q9Y4K0 1/20 0.47
▸ CCNC P24863 1/20 0.47
▸ CDK8 P49336 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ MTNR1A P48039 3/20 0.46
▸ MTNR1B P49286 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ EGFR P00533 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ FLT1 P17948 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7208445 0.85 CYP4F2 (0.60) KDM4ELOXL2CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL5177349 0.83 LOXL2 (0.43) KDM4ELOXL2CYP1A2MTNR1AMTNR1B
SCHEMBL17537545 0.82 ALDH1A1 (0.54) KDM4ECCNCCDK8CYP1A2ALDH1A1
SCHEMBL1650885 0.81 CYP1A2 (0.55) KDM4ELOXL2CCNCCDK8CYP1A2
SCHEMBL21820692 0.80 LOXL2 (0.49) LOXL2CYP1A2MTNR1AMTNR1BALDH1A1
SCHEMBL5514406 0.80 LOXL2 (0.51) KDM4ELOXL2CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL2846594 0.79 CYP1A2 (0.42) LOXL2CYP1A2MTNR1AMTNR1BALDH1A1
SCHEMBL13604226 0.78 ALDH1A1 (0.55) KDM4ELOXL2CYP1A2MTNR1AMTNR1B
SCHEMBL22345389 0.78 KDM4E (0.49) KDM4ECCNCCDK8CYP1A2ALDH1A1
Iodide SCHEMBL22345444 0.77 KDM4E (0.46) KDM4ECCNCCDK8CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5939268-A DIELS-ALDER REACTION PRODUCT OF A DIENE AND A DIENOPHILE; CHEMICAL INTERMEDIATES FOR DRUGS, SOLID PHASE SYNTHESIS THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 — — US claimed
EP-0773953-A1 COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME THE SCRIPPS INSTITUTE (US) 1997-05-21 — — EP claimed
WO-1996003424-A1 COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME THE SCRIPPS RESEARCH INSTITUTE (US) 1996-02-08 — — WO claimed
US-20090105301-A1 9A-SUBSTITUTED AZALIDES FOR THE TREATMENT OF MALARIA GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) 2009-04-23 — — US disclosed
US-20090105301-A1 9A-SUBSTITUTED AZALIDES FOR THE TREATMENT OF MALARIA GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) 2009-04-23 — — US disclosed
US-20090105301-A1 9A-SUBSTITUTED AZALIDES FOR THE TREATMENT OF MALARIA GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) 2009-04-23 — — US disclosed
EP-2012776-A2 9A-SUBSTITUTED AZALIDES GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) 2009-01-14 — — EP disclosed
WO-2007125414-A2 9A-SUBSTITUTED AZALIDES FOR THE TRATMENT OF MALARIA GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) 2007-11-08 — — WO disclosed
WO-2007125414-A2 9A-SUBSTITUTED AZALIDES FOR THE TRATMENT OF MALARIA GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) 2007-11-08 — — WO disclosed
US-5939268-A DIELS-ALDER REACTION PRODUCT OF A DIENE AND A DIENOPHILE; CHEMICAL INTERMEDIATES FOR DRUGS, SOLID PHASE SYNTHESIS THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 — — US disclosed
EP-0773953-A1 COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME THE SCRIPPS INSTITUTE (US) 1997-05-21 — — EP disclosed
WO-1996003424-A1 COMBINATORIAL LIBRARIES OF MOLECULES AND METHODS FOR PRODUCING SAME THE SCRIPPS RESEARCH INSTITUTE (US) 1996-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105301-A1 9A-SUBSTITUTED AZALIDES FOR THE TREATMENT OF MALARIA DHCR7, DHODH, QDPR KDM4E 104/4885LOXL2 4644/4885CCNC 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback